Treatment Outcome of Clonal Cytopenias of Undetermined Significance: a Single-institution Retrospective Study

Overview

Journal Blood Cancer J

Date 2021 Mar 2

PMID 33649321

Citations 9

Authors

Zhuoer Xie

Ahmad Nanaa

Antoine N Saliba

Rong He

David Viswanatha

Phuong Nguyen

Dragan Jevremovic

Patricia Greipp

Mohamad E Salama

Naseema Gangat

Hassan B Alkhateeb

Ayalew Tefferi

Mark Litzow

Mrinal Patnaik

Mithun Shah

Aref Al-Kali

Affiliations

Soon will be listed here.

Citing Articles

High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations.

Xie Z, Fernandez J, Lasho T, Finke C, Amundson M, McCullough K Blood. 2024; 144(23):2456-2461.

PMID: 39352751 PMC: 11628862. DOI: 10.1182/blood.2024024962.

Rapid and sustained response to luspatercept and eltrombopag combined treatment in one case of clonal cytopenias of undetermined significance with prior failure to cyclosporin and androgen therapy: a case report.

Xu J, Yan Y, Zong S, Ye W, Zheng J, Min C Ther Adv Hematol. 2024; 15:20406207241260353.

PMID: 38911444 PMC: 11191611. DOI: 10.1177/20406207241260353.

The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance.

Li M, Baranwal A, Gurney M, Shah S, Al-Kali A, Alkhateeb H Blood Adv. 2024; 8(12):3130-3139.

PMID: 38564774 PMC: 11222944. DOI: 10.1182/bloodadvances.2023012357.

How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome.

Xian R Hematology Am Soc Hematol Educ Program. 2023; 2023(1):51-58.

PMID: 38066895 PMC: 10727009. DOI: 10.1182/hematology.2023000420.

The kids are alright: MDS clones mature.

Rao S Blood. 2023; 141(11):1243-1245.

PMID: 36929441 PMC: 10163310. DOI: 10.1182/blood.2022019187.

References

Franceschi C, Campisi J . Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014; 69 Suppl 1:S4-9. DOI: 10.1093/gerona/glu057. View

Bejar R . CHIP, ICUS, CCUS and other four-letter words. Leukemia. 2017; 31(9):1869-1871. DOI: 10.1038/leu.2017.181. View

Kwok B, Hall J, Witte J, Xu Y, Reddy P, Lin K . MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood. 2015; 126(21):2355-61. PMC: 4653764. DOI: 10.1182/blood-2015-08-667063. View

Cheson B, Greenberg P, Bennett J, Lowenberg B, Wijermans P, Nimer S . Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108(2):419-25. DOI: 10.1182/blood-2005-10-4149. View

Xie M, Lu C, Wang J, McLellan M, Johnson K, Wendl M . Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014; 20(12):1472-8. PMC: 4313872. DOI: 10.1038/nm.3733. View

He R, Devine D, Tu Z, Mai M, Chen D, Nguyen P . Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. Mod Pathol. 2019; 33(3):334-343. PMC: 7051912. DOI: 10.1038/s41379-019-0359-9. View

Steensma D, Bejar R, Jaiswal S, Lindsley R, Sekeres M, Hasserjian R . Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015; 126(1):9-16. PMC: 4624443. DOI: 10.1182/blood-2015-03-631747. View

Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J . SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. 2020; 136(2):157-170. PMC: 7362582. DOI: 10.1182/blood.2020004850. View

Steensma D . Clinical Implications of Clonal Hematopoiesis. Mayo Clin Proc. 2018; 93(8):1122-1130. DOI: 10.1016/j.mayocp.2018.04.002. View

10.

Malcovati L, Galli A, Travaglino E, Ambaglio I, Rizzo E, Molteni E . Clinical significance of somatic mutation in unexplained blood cytopenia. Blood. 2017; 129(25):3371-3378. PMC: 5542849. DOI: 10.1182/blood-2017-01-763425. View

11.

Cargo C, Rowbotham N, Evans P, Barrans S, Bowen D, Crouch S . Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood. 2015; 126(21):2362-5. DOI: 10.1182/blood-2015-08-663237. View